Two patent disclosures signaled fresh small-molecule efforts in oncology and immune disorders: Kymera filed STAT6 inhibitors intended for cancer and inflammatory diseases, while Schrödinger disclosed mutant EGFR inhibitors aimed at resistant tumor variants. Kymera’s STAT6 program targets a transcription factor linked to tumor-supportive inflammation and allergic pathways; the company frames STAT6 degradation/inhibition as a route to modulate tumor microenvironments. Schrödinger’s patent shows a series of mutant-selective EGFR binders designed to address oncogenic EGFR alleles that evade current inhibitors. Both filings expand the preclinical inhibitor landscape and may accelerate partnerships or licensing discussions. Clarification: STAT6 is a transcription factor involved in IL‑4/IL‑13 signaling; mutant EGFR inhibitors aim to selectively inhibit oncogenic kinase variants while sparing wild-type EGFR to reduce toxicity.